CD279 (PD-1) Monoclonal Antibody (MIH4), eBioscience™ | Invitrogen 14-9969-37 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CD279 (PD-1) Monoclonal Antibody (MIH4), eBioscience™

catalog :

14-9969-37

quantity :

2 mg

price :

US 1372

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

MIH4

reactivity :

human

application :

immunohistochemistry, flow cytometry, immunohistochemistry - frozen section

more info or order :

Invitrogen product webpage

citations: 22

Published Application/Species/Sample/Dilution	Reference
flow cytometry; human; loading ...; fig 4b	Liu G, Yu Y, Feng F, Zhu P, Zhang H, Zhang D, et al. Human CD8+CD28- T suppressor cells expanded by common gamma chain (γc) cytokines retain steady allospecific suppressive capacity in vivo. BMC Immunol. 2020;21:23 pubmed publisher
	Kotetsu Y, Yanagihara T, Suzuki K, Ando H, Eto D, Hata K, et al. Imaging Changes and Immune-Checkpoint Expression on T Cells in Bronchoalveolar Lavage Fluid from Patients with Pulmonary Sarcoidosis. Biomedicines. 2021;9: pubmed publisher
	Xu X, Hou B, Fulzele A, Masubuchi T, Zhao Y, Wu Z, et al. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J Cell Biol. 2020;219: pubmed publisher
	Dötzer K, Schlüter F, Schoenberg M, Bazhin A, von Koch F, Schnelzer A, et al. Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. Cancers (Basel). 2019;11: pubmed publisher
	Yang W, Lee K, Srivastava R, Kuo F, Krishna C, Chowell D, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019;25:767-775 pubmed publisher
	Zhao Y, Harrison D, Song Y, Ji J, Huang J, Hui E. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Rep. 2018;24:379-390.e6 pubmed publisher
	Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018;215:985-997 pubmed publisher
	Gong Q, Zhu Y, Pang N, Ai H, Gong X, La X, et al. Increased levels of CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells, and associated factors Bcl-6, CXCR5, IL-21 and IL-6 contribute to repeated implantation failure. Exp Ther Med. 2017;14:5931-5941 pubmed publisher
	Gu Trantien C, Migliori E, Buisseret L, de Wind A, Brohée S, Garaud S, et al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight. 2017;2: pubmed publisher
	Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
	Komdeur F, Wouters M, Workel H, Tijans A, Terwindt A, Brunekreeft K, et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRÎ±Î²+ CD8Î±Î²+ T cells that can be targeted for cancer immunotherapy. Oncotarget. 2016;7:75130-75144 pubmed publisher
	Gulati N, SuÃ¡rez FariÃ±as M, Correa Da Rosa J, Krueger J. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res. 2015;4:149 pubmed publisher
	Cheng L, Tang X, Liu L, Peng J, Nishiura K, Cheung A, et al. Monoclonal antibodies specific to human Î”42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. MAbs. 2015;7:620-9 pubmed publisher
	Wolchinsky R, Hod Marco M, Oved K, Shen Orr S, Bendall S, Nolan G, et al. Antigen-dependent integration of opposing proximal TCR-signaling cascades determines the functional fate of T lymphocytes. J Immunol. 2014;192:2109-19 pubmed publisher
	Khalid M, Yu H, Sauter D, Usmani S, Schmökel J, Feldman J, et al. Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection. J Virol. 2012;86:4906-20 pubmed publisher
	Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011;15:R70 pubmed publisher
	Benson D, Bakan C, Mishra A, Hofmeister C, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286-94 pubmed publisher
	Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009;183:4984-93 pubmed publisher
	van Velzen M, Laman J, Kleinjan A, Poot A, Osterhaus A, Verjans G. Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype. J Immunol. 2009;183:2456-61 pubmed publisher
	Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57 pubmed publisher
	Zhang J, Zhang Z, Wang X, Fu J, Yao J, Jiao Y, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood. 2007;109:4671-8 pubmed
	Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-34 pubmed

product information

Product Type :

Antibody

Product Name :

CD279 (PD-1) Monoclonal Antibody (MIH4), eBioscience™

Catalog # :

14-9969-37

Quantity :

2 mg

Price :

US 1372

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 1 µg/test, Immunohistochemistry (Frozen): Assay-Dependent

Species :

Human

Clone :

MIH4

Isotype :

IgG1, kappa

Storage :

4° C

Description :

Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 1 µg/test, Immunohistochemistry (Frozen): Assay-Dependent

Aliases :

CD279; EGK_05005; hPD1; hPD-1; hPD-l; hSLE1; Ly101; mPD-1; PD1; PD-1; Pdc1; Pdcd1; programmed cell death 1; programmed cell death 1 protein; programmed cell death protein 1; programmed cell death protein 1-like; programmed death 1; Protein PD1; Protein PD-1; sCD279; SLEB2; soluble CD279; systemic lupus erythematosus susceptibility 2

more info or order :

Invitrogen product webpage